Daito Pharmaceutical Co., Ltd. (JP:4577)
:4577
4577 Stock Chart & Stats
¥1356.00
-¥13.00(-0.64%)
At close: 4:00 PM EST
¥1356.00
-¥13.00(-0.64%)
Day’s Range― - ―
52-Week Range¥970.00 - ¥1,521.00
Previous CloseN/A
Volume21.10K
Average Volume (3M)63.87K
Market Cap
¥43.15B
Enterprise Value¥51.18B
Total Cash (Recent Filing)¥2.15B
Total Debt (Recent Filing)¥11.94B
Price to Earnings (P/E)18.3
Beta0.27
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.75%
Share Statistics
EPS (TTM)N/A
Shares Outstanding30,096,880
10 Day Avg. Volume54,390
30 Day Avg. Volume63,866
Financial Highlights & Ratios
PEG Ratio-0.39
Price to Book (P/B)0.58
Price to Sales (P/S)0.59
P/FCF Ratio-31.31
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Contract Manufacturing And API Supply FocusDaito's core business is contract manufacturing and API production, a durable services-driven model with long-term commercial relationships. Serving branded and generic supply chains provides recurring revenue and diversification across customers and product types, supporting stable demand over 2–6 months.
Consistent Revenue Growth TrendThe company shows multi-year top-line expansion, with reported revenue growth near 6–8%. Sustained sales growth indicates continued commercial traction for its manufacturing services and product mix, providing a structural buffer to support reinvestment and scale economies over the medium term.
Stable Equity Ratio / Solid Capital StructureDespite rising leverage, management has maintained a stable equity ratio and a solid capital base. This structural strength supports creditor confidence and gives the company capacity to fund operations or selective investments without immediate equity dilution, aiding medium-term resilience.
Bears Say
Material Margin CompressionSignificant deterioration in gross and net margins signals structural pressure from rising costs, pricing competition, or product-mix shifts. Lower margins erode the company's ability to convert revenue into sustainable profits, limiting reinvestment capacity and exposing earnings to downside over the next several quarters.
Negative Free Cash Flow TrendPersistently negative free cash flow and a steep decline in FCF growth hamper the firm's capacity to self-fund capital expenditure, support dividends, or reduce debt. Even with operating cash generation present, weak FCF suggests structural cash conversion issues that can constrain strategic flexibility.
Rising Leverage And Falling ROEA noticeable rise in leverage coupled with sharply lower ROE indicates the company is using more debt while generating lower returns for shareholders. This combination reduces financial flexibility and increases vulnerability to cost or demand shocks, weakening long-term shareholder value creation.
Daito Pharmaceutical Co., Ltd. News
4577 FAQ
What was Daito Pharmaceutical Co., Ltd.’s price range in the past 12 months?
Daito Pharmaceutical Co., Ltd. lowest stock price was ¥970.00 and its highest was ¥1521.00 in the past 12 months.
What is Daito Pharmaceutical Co., Ltd.’s market cap?
Daito Pharmaceutical Co., Ltd.’s market cap is ¥43.15B.
When is Daito Pharmaceutical Co., Ltd.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Daito Pharmaceutical Co., Ltd.’s earnings last quarter?
Currently, no data Available
Is Daito Pharmaceutical Co., Ltd. overvalued?
According to Wall Street analysts Daito Pharmaceutical Co., Ltd.’s price is currently Overvalued.
Does Daito Pharmaceutical Co., Ltd. pay dividends?
Daito Pharmaceutical Co., Ltd. pays a Semiannually dividend of ¥20 which represents an annual dividend yield of 2.75%. See more information on Daito Pharmaceutical Co., Ltd. dividends here
What is Daito Pharmaceutical Co., Ltd.’s EPS estimate?
Daito Pharmaceutical Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Daito Pharmaceutical Co., Ltd. have?
Daito Pharmaceutical Co., Ltd. has 30,096,880 shares outstanding.
What happened to Daito Pharmaceutical Co., Ltd.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Daito Pharmaceutical Co., Ltd.?
Currently, no hedge funds are holding shares in JP:4577
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Daito Pharmaceutical Co., Ltd.
Daito Pharmaceutical Co.,Ltd. manufactures and sells pharmaceutical products worldwide. The company offers various active pharmaceutical ingredients and intermediates, prescription drugs, OTC drugs, and home-delivery medicines; formulations in various forms, such as tablets, capsules, troches, granules, and powders; and contract manufacturing services for formulations of medicinal products to pharmaceutical companies. It also sells health food products. The company was formerly known as Daito Corporation and changed its name to Daito Pharmaceutical Co.,Ltd. in 1992. Daito Pharmaceutical Co.,Ltd. was incorporated in 1942 and is headquartered in Toyama, Japan.
Technical Analysis
Fuji Pharma Co., Ltd.
―
Mochida Pharmaceutical Co., Ltd.
―
Nippon Chemiphar Co., Ltd.
―
KYORIN Pharmaceutical Co.,Ltd.
―
ASKA Pharmaceutical Holdings Co., Ltd.
―
Options Prices
Currently, No data available
---